OpenText process and document management solutions for pharmaceutical & life sciences conference

13 - 14 May 2013, Kassel, Germany.
OpenText solutions for the Pharmaceutical and Life Sciences industries support critical processes where compliant management of all paper and electronic records and documents is essential. You are invited to attend the Comprehensive Process and Document Management Life Science Conference held in Kassel, Germany. Join this conference to learn about the GxP Compliance, Document Management in CMC, Computer System Validation and other topics with the "Ask the Experts" session.

Get an Free Onsite Visit at B. Braun in Melsungen and watch how B. Braun made the switch from EMC Documentum to OpenText Regulated Documents.

OpenText will present for the first time the newest Solutions for Business Process Management "ASSURE for Regulated Documents" on this conference.

Visit this life science event and get an onsite visit at B. Braun in Melsungen (Germany) for free and have an "Ask the Experts" session on the 13th May. The onsite visit includes as well the networking dinner.

Follow this link and register today for the free "Onsite Visit" at B. Braun, B. Braun is one of the world's leading healthcare suppliers. Their four divisions orient their products and services toward different medical fields: hospital, surgery, private practice (medical care and doctors' offices) and extra-corporeal blood treatment.

Registration web link (in German language)

About OpenText
OpenText is the leader in Enterprise Information Management (EIM). EIM enables organizations to grow the business, lower costs of operations, and reduce information governance and security related risks. OpenText focuses on the key drivers of business success to improve business insight, strengthen business impact, accelerate process velocity, address information governance and provide security.

Most Popular Now

Scientists uncover SARS-CoV-2-specific T cell immu…

The study by scientists from Duke-NUS Medical School, in close collaboration with the National University of Singapore (NUS) Yong Loo Lin School of Medicine, Singapore Ge...

Researchers call for worldwide biosurveillance net…

The emergence of COVID-19 is a powerful reminder of how unchecked wildlife trade can lead to the spillover spread of viruses between wildlife and humans. Understanding th...

Common FDA-approved drug may effectively neutraliz…

A common drug, already approved by the Food and Drug Administration (FDA), may also be a powerful tool in fighting COVID-19, according to research published this week in ...

New study supports remdesivir as COVID-19 treatmen…

The news about remdesivir, the investigational anti-viral drug that has shown early promise in the fight against COVID-19, keeps getting better. This week researchers at ...

Drug linked to 45% lower risk of dying among COVID…

Critically ill COVID-19 patients who received a single dose of a drug that calms an overreacting immune system were 45% less likely to die overall, and more likely to be ...

Neutralizing antibodies in the battle against COVI…

An important line of defence in the fight against the new corona virus SARS-CoV-2 is the formation of neutralising antibodies. These can eliminate the intruders and have ...

Pfizer and BioNTech granted FDA Fast Track designa…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced that two of the companies' four investigational vaccine candidates from their BNT162 mRNA-bas...

Sanofi and Regeneron provide update on Kevzara┬« (s…

Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that the U.S. Phase 3 trial of Kevzara® (sarilumab) 400 mg in COVID-19 patients requiring mechanical v...

GSK and CureVac announce strategic mRNA technology…

GlaxoSmithKline plc (LSE/NYSE: GSK) and CureVac announced the signing of a strategic collaboration agreement for the research, development, manufacturing and commercialis...

Novartis launches first-of-its-kind not-for-profit…

Novartis announced a new initiative to help patients in low-income and lower-middle-income countries (LIC; LMIC) access affordable medicines to treat the major symptoms o...

COVID-19 vaccine AZD1222 showed robust immune resp…

Interim results from the ongoing Phase I/II COV001 trial, led by Oxford University, showed AZD1222 was tolerated and generated robust immune responses against the SARS-Co...

Neutralizing antibodies isolated from COVID-19 pat…

Researchers at Columbia University Irving Medical Center have isolated antibodies from several COVID-19 patients that, to date, are among the most potent in neutralizing ...